Premium
PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP
Author(s) -
Al Tabaa Y.,
Casasnovas O.,
Baillet C.,
Bachy E.,
Virelizier E. Nicolas,
Schiano de Colella J. M.,
Bailly C.,
Kanoun S.,
Guidez S.,
Gyan E.,
Gressin R.,
Morineau N.,
Ysebaert L.,
Le Gouill S.,
Tilly H.,
Houot R.,
Morschhauser F.,
Cartron G.,
Herbaux C.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.157_2880
Subject(s) - medicine , atezolizumab , obinutuzumab , oncology , rituximab , neutropenia , surrogate endpoint , regimen , avidity , clinical trial , lymphoma , cancer , immunotherapy , chemotherapy , immunology , nivolumab , antibody